MS4A1 and non-Hodgkin lymphoma: 90Yttrium ibritumomab tiuxetan (Zevalin), an anti-CD20 antibody conjugated to the radioactive isotope 90Yttrium, was the first radioimmunotherapy drug approved for cancer treatment, when it was FDA-approved in 2002 for the treatment of NHL [90].